Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-065660
Filing Date
2025-05-07
Accepted
2025-05-07 16:10:24
Documents
69
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rvmd-20250331.htm   iXBRL 10-Q 2749470
2 EX-10.1 rvmd-ex10_1.htm EX-10.1 56294
3 EX-31.1 rvmd-ex31_1.htm EX-31.1 17298
4 EX-31.2 rvmd-ex31_2.htm EX-31.2 17257
5 EX-32.1 rvmd-ex32_1.htm EX-32.1 9020
6 EX-32.2 rvmd-ex32_2.htm EX-32.2 9010
  Complete submission text file 0000950170-25-065660.txt   10553178

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rvmd-20250331.xsd EX-101.SCH 1188172
72 EXTRACTED XBRL INSTANCE DOCUMENT rvmd-20250331_htm.xml XML 2142926
Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Filer) CIK: 0001628171 (see all company filings)

EIN.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39219 | Film No.: 25921441
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)